Anti-CTH (Aa 250-350) Polyclonal Antibody (DPABH-26846) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

Total Page：16

File Type：pdf, Size：1020Kb

Anti-CTH (aa 250-350) polyclonal antibody (DPABH-26846) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Catalyzes the last step in the transsulfuration pathway from methionine to cysteine. Has broad substrate specificity. Converts cystathionine to cysteine, ammonia and 2-oxobutanoate. Converts two cysteine molecules to lanthionine and hydrogen sulfide. Can also accept homocysteine as substrate. Specificity depends on the levels of the endogenous substrates. Generates the endogenous signaling molecule hydrogen sulfide (H2S), and so contributes to the regulation of blood pressure. Immunogen Synthetic peptide conjugated to KLH derived from within residues 250 - 350 of Human Cystathionase. Isotype IgG Source/Host Rabbit Species Reactivity Human Purification Immunogen affinity purified Conjugate Unconjugated Applications WB, ICC/IF Format Liquid Size 100 μg Buffer pH: 7.40; Constituent: PBS Preservative 0.02% Sodium Azide Storage Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. GENE INFORMATION Gene Name CTH cystathionase (cystathionine gamma-lyase) [ Homo sapiens ] 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Official Symbol CTH Synonyms CTH; cystathionase (cystathionine gamma-lyase); cystathionine gamma-lyase; gamma- cystathionase; homoserine deaminase; cysteine desulfhydrase; homoserine dehydratase; cysteine-protein sulfhydrase; Entrez Gene ID 1491 Protein Refseq NP_001177392.1 UniProt ID P32929 Pathway Biosynthesis of amino acids; Cysteine and methionine metabolism; Cysteine biosynthesis, homocysteine + serine => cysteine; Cysteine formation from homocysteine Function L-cysteine desulfhydrase activity; L-cystine L-cysteine-lyase (deaminating); calmodulin binding; carbon-sulfur lyase activity 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.

Copy Link

Recommended publications

Identification and Characterization of Enzymes Involved in Post- Translational Modifications of Phycobiliproteins in the Cyanobacterium Synechocystis Sp
University of New Orleans ScholarWorks@UNO University of New Orleans Theses and Dissertations Dissertations and Theses 8-8-2007 Identification and Characterization of Enzymes Involved in Post- translational Modifications of Phycobiliproteins in the Cyanobacterium Synechocystis sp. PCC 6803 Crystal Miller University of New Orleans Follow this and additional works at: https://scholarworks.uno.edu/td Recommended Citation Miller, Crystal, "Identification and Characterization of Enzymes Involved in Post-translational Modifications of Phycobiliproteins in the Cyanobacterium Synechocystis sp. PCC 6803" (2007). University of New Orleans Theses and Dissertations. 572. https://scholarworks.uno.edu/td/572 This Thesis is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights- holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself. This Thesis has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact [email protected]. Identification and Characterization of Enzymes Involved in Post-translational Modifications of Phycobiliproteins in the Cyanobacterium Synechocystis sp. PCC 6803 A Thesis Submitted to the Graduate Faculty of the University of New Orleans in partial fulfillment of the requirements for degree of Master of Science in Biological Sciences by Crystal Miller B.S. University of New Orleans, 2004 August, 2007 ACKNOWLEDGMENTS I would first like to thank my fiancé, Gus Mugnier, for always being there for me and supporting me through my graduate career.
[Show full text]
Orphan Enzymes Could Be an Unexplored Reservoir of New Drug Targets
Drug Discovery Today Volume 11, Numbers 7/8 April 2006 REVIEWS Reviews GENE TO SCREEN Orphan enzymes could be an unexplored reservoir of new drug targets Olivier Lespinet and Bernard Labedan Institut de Geńe´tique et Microbiologie, CNRS UMR 8621, Universite´ Paris Sud, Baˆtiment 400, 91405 Orsay Cedex, France Despite the immense progress of genomics, and the current availability of several hundreds of thousands of amino acid sequences, >39% of well-defined enzyme activities (as represented by enzyme commission, EC, numbers) are not associated with any sequence. There is an urgent need to explore the 1525 orphan enzymes (enzymes having EC numbers without an associated sequence) to bridge the wide gap that separates knowledge of biochemical function and sequence information. Strikingly, orphan enzymes can even be found among enzymatic activities successfully used as drug targets. Here, knowledge of sequence would help to develop molecular-targeted therapies, suppressing many drug-related side-effects. Biology is exploring numerous and diverse fields, each of which discovered before, despite intensive research by thousands of is very complex and difficult to study in its entirety. For many people studying the genetics and biochemistry of Saccharomyces years, immense advances in disclosing molecular functions have cerevisiae over the past 50 years. This observation has been con- been made using reductionist approaches, such as molecular firmed repeatedly, with the cohort of genomes that have been biology. Combining genetic, biophysical and biochemical con- sequenced, at a steady pace, over the past ten years. We now know cepts and methodologies has helped to disclose details of com- that many genes have been missed by reductionist approaches plex molecular mechanisms such as DNA replication.
[Show full text]
X-Ray Fluorescence Analysis Method Röntgenfluoreszenz-Analyseverfahren Procédé D’Analyse Par Rayons X Fluorescents
(19) & (11) EP 2 084 519 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 23/223 (2006.01) G01T 1/36 (2006.01) 01.08.2012 Bulletin 2012/31 C12Q 1/00 (2006.01) (21) Application number: 07874491.9 (86) International application number: PCT/US2007/021888 (22) Date of filing: 10.10.2007 (87) International publication number: WO 2008/127291 (23.10.2008 Gazette 2008/43) (54) X-RAY FLUORESCENCE ANALYSIS METHOD RÖNTGENFLUORESZENZ-ANALYSEVERFAHREN PROCÉDÉ D’ANALYSE PAR RAYONS X FLUORESCENTS (84) Designated Contracting States: • BURRELL, Anthony, K. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Albrecht, Thomas Kraus & Weisert (30) Priority: 10.10.2006 US 850594 P Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 (43) Date of publication of application: 80539 München (DE) 05.08.2009 Bulletin 2009/32 (56) References cited: (60) Divisional application: JP-A- 2001 289 802 US-A1- 2003 027 129 12164870.3 US-A1- 2003 027 129 US-A1- 2004 004 183 US-A1- 2004 017 884 US-A1- 2004 017 884 (73) Proprietors: US-A1- 2004 093 526 US-A1- 2004 235 059 • Los Alamos National Security, LLC US-A1- 2004 235 059 US-A1- 2005 011 818 Los Alamos, NM 87545 (US) US-A1- 2005 011 818 US-B1- 6 329 209 • Caldera Pharmaceuticals, INC. US-B2- 6 719 147 Los Alamos, NM 87544 (US) • GOLDIN E M ET AL: "Quantitation of antibody (72) Inventors: binding to cell surface antigens by X-ray • BIRNBAUM, Eva, R.
[Show full text]
Sulfur Metabolism in Escherichia Coli and Related Bacteria: Facts and Fiction
J. Mol. Microbiol. Biotechnol. (2000) 2(2): 145-177. Sulfur Metabolism inJMMB Enterobacteria Review 145 Sulfur Metabolism in Escherichia coli and Related Bacteria: Facts and Fiction Agnieszka Sekowska1,2, Hsiang-Fu Kung3, sulfur metabolism (anabolism, transport and catabolism and Antoine Danchin1,2* and recycling), then emphasize the special situation of the metabolism of S-adenosylmethionine (AdoMet), ending 1Hong Kong University Pasteur Research Centre, with special situations where sulfur is involved, in particular Dexter Man Building, 8, Sassoon Road, synthesis of coenzyme and prosthetic groups as well as Pokfulam, Hong Kong tRNA modifications. Finally, we point to the chemical kinship 2Regulation of Gene Expression, Institut Pasteur, between sulfur and selenium, a building block of the 21st 28 rue du Docteur Roux, 75724 Paris Cedex 15, France amino acid in proteins, selenocysteine. 3Institute of Molecular Biology, The University of Hong Kong, South Wing, General Sulfur Metabolism 8/F Kadoorie Biological Sciences Bldg., Pokfulam Road, Hong Kong In the general metabolism of sulfur one must distinguish three well differentiated aspects: synthesis of the sulfur- containing amino acids (cysteine and methionine), together Abstract with that of the sulfur-containing coenzymes or prosthetic groups; catabolism and equilibration of the pool of sulfur Living organisms are composed of macromolecules containing molecules; and methionine recycling (a topic in made of hydrogen, carbon, nitrogen, oxygen, itself, because of the role of methionine as the first residue phosphorus and sulfur. Much work has been devoted of all proteins). Five databases for metabolism allow one to the metabolism of the first five elements, but much to retrieve extant data relevant to sulfur metabolism: the remains to be understood about sulfur metabolism.
[Show full text]
12) United States Patent (10
US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
[Show full text]
All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
[Show full text]
Hydrogen Sulfide Is a Weak Acid with Pka~7.0 (Figure 1)
antioxidants Review Biosynthesis, Quantification and Genetic Diseases of the Smallest Signaling Thiol Metabolite: Hydrogen Sulfide Joanna Myszkowska 1, Ilia Derevenkov 2 , Sergei V. Makarov 2, Ute Spiekerkoetter 3 and Luciana Hannibal 1,* 1 Laboratory of Clinical Biochemistry and Metabolism, Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; [email protected] 2 Department of Food Chemistry, Ivanovo State University of Chemistry and Technology, 153000 Ivanovo, Russia; [email protected] (I.D.); [email protected] (S.V.M.) 3 Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; [email protected] * Correspondence: [email protected] Abstract: Hydrogen sulfide (H2S) is a gasotransmitter and the smallest signaling thiol metabolite with important roles in human health. The turnover of H2S in humans is mainly governed by enzymes of sulfur amino acid metabolism and also by the microbiome. As is the case with other small signaling molecules, disease-promoting effects of H2S largely depend on its concentration and compartmentalization. Genetic defects that impair the biogenesis and catabolism of H2S have been described; however, a gap in knowledge remains concerning physiological steady-state concentra- tions of H2S and their direct clinical implications. The small size and considerable reactivity of H2S Citation: Myszkowska, J.; renders its quantification in biological samples an experimental challenge. A compilation of methods Derevenkov, I.; Makarov, S.V.; currently employed to quantify H2S in biological specimens is provided in this review. Substan- Spiekerkoetter, U.; Hannibal, L.
[Show full text]
Purification of Lysine Decarboxylase: a Model System for Plp Enzyme Inhibitor Development and Study
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Student Research Projects, Dissertations, and Theses - Chemistry Department Chemistry, Department of 5-2011 PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM FOR PLP ENZYME INHIBITOR DEVELOPMENT AND STUDY Leah C. Zohner University of Nebraska-Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/chemistrydiss Part of the Chemistry Commons Zohner, Leah C., "PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM FOR PLP ENZYME INHIBITOR DEVELOPMENT AND STUDY" (2011). Student Research Projects, Dissertations, and Theses - Chemistry Department. 21. https://digitalcommons.unl.edu/chemistrydiss/21 This Article is brought to you for free and open access by the Chemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Student Research Projects, Dissertations, and Theses - Chemistry Department by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM FOR PLP ENZYME INHIBITOR DEVELOPMENT AND STUDY By Leah Zohner A THESIS Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Master of Science Major: Chemistry Under the Supervision of Professor David B. Berkowitz Lincoln, Nebraska May, 2011 PURIFICATION OF LYSINE DECARBOXYLASE: A MODEL SYSTEM FOR PLP ENZYME INHIBITOR DEVELOPMENT AND STUDY Leah Zohner, M.S. University of Nebraska, 2011 Advisor: David Berkowitz Pyridoxal phosphate (PLP) dependent enzymes have the ability to manipulate amino acid substrates, serving variously as (i) racemases, transaminases, and beta- or gamma eliminases (all involving Cα-H bond cleavage); (ii) decarboxylases (Cα-CO2- bond cleavage), or (iii) retroaldolases (Cα-Cβ bond cleavage).
[Show full text]
The Transsulfuration Pathway: a Source of Cysteine for Glutathione in Astrocytes
Amino Acids (2012) 42:199–205 DOI 10.1007/s00726-011-0864-8 REVIEW ARTICLE The transsulfuration pathway: a source of cysteine for glutathione in astrocytes Gethin J. McBean Received: 20 December 2010 / Accepted: 17 February 2011 / Published online: 3 March 2011 Ó Springer-Verlag 2011 Abstract Astrocyte cells require cysteine as a substrate NF-jB Nuclear factorjB for glutamate cysteine ligase (c-glutamylcysteine synthase; SAPK Stress-activated protein kinase EC 6.3.2.2) catalyst of the rate-limiting step of the TNFa Tumour necrosis factora - c-glutamylcycle leading to formation of glutathione (L-c- xCT Subunit of the xc cystine-glutamate exchanger glutamyl-L-cysteinyl-glycine; GSH). In both astrocytes and glioblastoma/astrocytoma cells, the majority of cysteine - originates from reduction of cystine imported by the xc cystine-glutamate exchanger. However, the transsulfura- An overview of sulfur amino acid metabolism tion pathway, which supplies cysteine from the indispens- and the transsulfuration pathway able amino acid, methionine, has recently been identiﬁed as a signiﬁcant contributor to GSH synthesis in astrocytes. Sulfur amino acid metabolism is critically important in The purpose of this review is to evaluate the importance of mammalian cells and is linked to provision of methyl the transsulfuration pathway in these cells, particularly in groups for a large number of biochemical processes. Die- the context of a reserve pathway that channels methionine tary methionine is activated by conversion to S-adenosyl- towards cysteine when the demand for glutathione is high, methionine in an ATP-dependent reaction catalysed by or under conditions in which the supply of cystine by the methionine adenosyltransferase that, through action of - xc exchanger may be compromised.
[Show full text]
C-S Bond Cleavage by a Polyketide Synthase Domain
C-S bond cleavage by a polyketide synthase domain Ming Maa,1, Jeremy R. Lohmana,1, Tao Liub,1, and Ben Shena,b,c,d,2 aDepartment of Chemistry, The Scripps Research Institute, Jupiter, FL 33458; bDivision of Pharmaceutical Sciences, University of Wisconsin-Madison, Madison, WI 53705; cDepartment of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458; and dNatural Products Library Initiative at The Scripps Research Institute, The Scripps Research Institute, Jupiter, FL 33458 Edited by Jerrold Meinwald, Cornell University, Ithaca, NY, and approved July 15, 2015 (received for review April 29, 2015) Leinamycin (LNM) is a sulfur-containing antitumor antibiotic featur- peptide-polyketide macrolactam backbone is synthesized by a hy- ing an unusual 1,3-dioxo-1,2-dithiolane moiety that is spiro-fused to brid NRPS-acyltransferase (AT)-less type I polyketide synthase a thiazole-containing 18-membered lactam ring. The 1,3-dioxo-1,2- (PKS), consisting of LnmQ (adenylation protein), LnmP (peptide dithiolane moiety is essential for LNM’s antitumor activity, by virtue carrier protein), LnmI (a hybrid NRPS-AT-less type I PKS), LnmJ of its ability to generate an episulfonium ion intermediate capable (PKS), and LnmG (AT) (21, 23, 24); (ii) the alkyl branch at C-3 of of alkylating DNA. We have previously cloned and sequenced the LNM is installed by a novel pathway for β-alkylation in polyketide lnm gene cluster from Streptomyces atroolivaceus S-140. In vivo and biosynthesis, featuring LnmK (AT/decarboxylase), LnmL (ACP), in vitro characterizations
[Show full text]